Ten Years of CERAB for Complex Aortoiliac Occlusive disease
DOI:
https://doi.org/10.48750/acv.682Keywords:
Aortoiliac disease, CERAB, Kissing stent, Peripheral arterial diseaseAbstract
INTRODUCTION: Covered Endovascular Aortic Repair (CERAB) has previously been shown to be a viable treatment option for patients with aortiliac occlusive disease. However, data reporting on the technique is still scarce, and durability remains a concern. The aim of this study was to conduct a descriptive analysis of our experience and to evaluate the outcomes of CERAB over the last 10 years.
METHODS: A retrospective, single- centre cohort study was conducted. From April 2015 to February 2025, we included all consecutive patients who underwent CERAB for aortiliac occlusive disease. Outcomes were defined as primary patency rate, freedom from clinically driven target lesion revascularisation, and amputation- free survival at 12 and 36 months. Major adverse events were defined as a composite of myocardial infarction, stroke, bowel ischemia, respiratory insufficiency, acute limb ischemia or access- related complications.
RESULTS: A total of 23 patients (65%)(65%) male) were included, with a mean age of 60.7 years (±10.2)(±10.2) . The most common clinical presentation was Rutherford classification grade 5 chronic ischemia (44%)(44%) , and the majority (87%)(87%) had Transatlantic Inter- Society Consensus II (TASC II) D lesions. Technical success was achieved in 100%100% of cases. Major adverse events at 30 days were observed in 39%39% , with access- related complications the most common (17%)(17%) . The median hospital stay was six days (range 3.0- 15), and 30- day mortality occurred in one case. The median follow- up was 27 months (4.6- 62.1). The primary patency rate was 84%84% and 77%77% at 12 and 36 months, respectively. The target lesion revascularisation freedom rate was 85%85% at 12 and 36 months, while the major amputation- free survival rate was 89%89% at the same time points.
CONCLUSION: The CERAB technique appears to be a feasible option for patients with extensive aortiliac occlusive disease, including TASC II D lesions, demonstrating high technical success. Despite the small sample size, good mid- term outcomes were observed in a clinical and anatomically complex group of patients.
Downloads
References
Norgren L, Hiatt WR, Dormandy JA, Nehler, Harris KA, Fowkes FGR. InterSociety Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45:S5-67.
Jebbink EG, Holewijn S, Slump CH, Lardenoije J-W, Reijnen MMPJ. Systematic Review of results of kissing stents in the Treatment of aortiiac Occlusive Disease. Ann Vasc Surg 2017;42:328-36.
Mwipatayi BP, Sharma S, Daneshmand A, Thomas SD, Vijayan V, Altaf N, et al. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortiiac occlusive disease. J Vasc Surg 2016;64:83-94
Jebbink EG, Mathai V, Boersen JT, Sun C, Slump CH, Goverde PCJM, et al. Hemodynamic comparison of stent configurations used for aortiiac occlusive disease. J Vasc Surg 2016;66:251-60
Grimme FAB, Spithoven JH, Zeebregts CJ, Scharn DM, Reijnen MMPJ. Endovascular Treatment of Occlusive Lesions in the Aortic Bifurcation with Kissing Polytetrafluoroethylene-Covered Stents. J Vasc Intervent Radiol 2015;26:1277-84.
Jebbink EG, Grimme FAB, Goverde PCJM, Van Oostayen JA, Slump CH, Reijnen MMPJ. Geometrical consequences of kissing stents and the Covered Endovascular Reconstruction of the Aortic Bifurcation configuration in an in vitro model for endovascular reconstruction of aortic bifurcation. J Vasc Surg 2014;61:1306-11.
Grimme FAB, Goverde PCJM, Verbruggen PJEM, Zeebregts CJ, Reijnen MMPJ. Editor's choice - First results of the covered endovascular Reconstruction of the Aortic Bifurcation (CERAB) technique for aortilloac occlusive disease. Eur J Vasc Endovasc Surg 2015;50:638-47.
Bontinis V, Bontinis A, Giannopoulos A, Manaki V, Kontes I, Papas T, et al. Covered endovascular reconstruction of the aortic bifurcation: A systematic review aggregated data and individual participant data meta-analysis. J Vasc Surg 2023;79:1525-35.
Semaan DB, Habib SG, Abdul-Malak OM, Siracuse JJ, Madigan MC, Salem KM, et al. Aortobifemoral bypass vs covered endovascular reconstruction of aortic bifurcation. J Vasc Surg 2024;80:459-65.
Taeymans K, Jebbink EG, Holewijn S, Martens JM, Versluis M, Goverde PCJM, et al. Three-year outcome of the covered endovascular reconstruction of the aortic bifurcation technique for aortilloac occlusive disease. J Vasc Surg 2017;67:1438-47.
Salem M, Hosny MS, Francia F, Sallam M, Saratzis A, Saha P, et al. Management of Extensive Aorto-lliac Disease: A Systematic Review and Meta-Analysis of 9319 patients. CardiolVasc Intervent Radiol 2021;44:1518-35.
Premaratne S, Newman J, Hobbs S, Garnham A, Wall M. Meta-analysis of direct surgical versus endovascular revascularization for aortilloac occlusive disease. J Vasc Surg 2020;72:726-37.
